ASCO 2025 Archives - SOHO Insider

Skip to content

Varun Bafna, MD, discusses phase 2 results of ofirnoflast in LR-MDS
The promise of CELMoDs in myeloma treatment
EHA. 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
How can trispecifics be integrated with CELMoDs in myeloma treatment?

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Dr. Du on unequal access to therapies in blood cancers

Cellular Therapy

Dr. Du on unequal access to therapies in blood cancers

Leukemia

Dr. Du on unequal access to therapies in blood cancers

Lymphoma

Dr. Du on unequal access to therapies in blood cancers

Multiple Myeloma

Dr. Du on unequal access to therapies in blood cancers

Myelodysplastic Syndromes

Dr. Du on unequal access to therapies in blood cancers

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

July 21, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Meetings / Conferences ASCO 2025

ASCO 2025

News and highlights from the 2025 ASCO meeting in Chicago.

upclose shot of woman wearing glasses and a white coat

ASCO 2025 News Video Interviews

Dr. Du on unequal access to therapies in blood cancers

by SOHO Insider Editors
September 12, 2025
0 Comments

ASCO 2025 News

Dr. Kuykendall discusses VERIFY trial, rusfertide’s impact on PV treatment

by Leah Sherwood
July 1, 2025
0 Comments

GGM ASCO/EHA

ASCO 2025 Video Interviews

Latest COMMANDS analysis shows luspatercept is transformative in MDS

by Leah Sherwood
June 24, 2025
0 Comments

SOHO Insider

ASCO 2025 Video Interviews

What do the real-world data show on luspatercept in LR-MDS?

by SOHO Insider Editors
June 23, 2025
0 Comments

Multiple Myeloma. Multiple Myeloma disease blood test inmedical laboratory

ASCO 2025

Isatuximab with KRd boosts sustained MRD negativity in myeloma

by SOHO Insider Editors
June 5, 2025
0 Comments

Dna,Gene,Helix,Spiral,Molecule,Structure

ASCO 2025 Meetings / Conferences

Phase 3 VERIFY study shows rusfertide significantly improves PV outcomes over SOC

by Leah Sherwood
June 4, 2025
0 Comments

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope

ASCO 2025

Sintilimab plus ICE regimen significantly improves complete remission in classical Hodgkin lymphoma

by SOHO Insider Editors
June 3, 2025
0 Comments

clipboard

ASCO 2025

Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML

by SOHO Insider Editors
June 1, 2025
0 Comments

Time to phase 3 symbol. Concept word Phase 1 2 3 on wooden block. Businessman hand. Beautiful grey table grey background. Business planning and time to phase 3 concept. Copy space.

ASCO 2025 Meetings / Conferences

Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma

by SOHO Insider Editors
May 31, 2025
0 Comments

pallatiative care

ASCO 2025 Meetings / Conferences

Early palliative care integration does not reduce MM patients’ healthcare utilization

by Leah Sherwood
May 28, 2025
0 Comments

Top Categories

Cellular Therapy

75

Leukemia

116

Lymphoma

132

Multiple Myeloma

113

Myelodysplastic Syndromes

41

Myeloproliferative Neoplasms

33

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Early palliative care integration does not reduce MM patients’ healthcare utilization

Cellular Therapy

Early palliative care integration does not reduce MM patients’ healthcare utilization

Leukemia

Early palliative care integration does not reduce MM patients’ healthcare utilization

Lymphoma

Early palliative care integration does not reduce MM patients’ healthcare utilization

Multiple Myeloma

Early palliative care integration does not reduce MM patients’ healthcare utilization

Myelodysplastic Syndromes

Early palliative care integration does not reduce MM patients’ healthcare utilization

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Varun Bafna, MD, discusses phase 2 results of ofirnoflast in LR-MDS

CELMoDs in myeloma treatment

The promise of CELMoDs in myeloma treatment

EHA. 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.